Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE-M: Nivolumab and Radiotherapy in Multiple Myeloma
NCT03634800Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Primary endpoint: Overall Response Rate at 12 weeks. Started Oct 2018; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03634800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634800.